Ainos enters addendum to product development agreement with affiliate TCNT; defines co-development products and fees

Ainos, Inc.

Addendum specifies co-development products: VOC diagnostics, AI Nose, POCT, VELDONA drug processing, lateral flow diagnostics.
Ainos to pay TCNT total fee of NT$5M (~USD$161k) over five years starting 2024.
Non-exclusive patent license for VOC and POCT: US$95k/month (plus 5% tax) for initial six months from Jan 2024.
TCNT provides facilities, equipment, mass production tech and ISO9001/13485 management; parts, raw materials, utilities excluded.
Original agreement effective Aug 2021 to Jul 2026; addendum ratified by audit committee on Jan 8, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ainos, Inc. amended Addendum Agreement with Taiwan Carbon Nano Technology Corporation valued at NT$5 million (approximately USD$161,000) (effective 2024-01-09).

Action: amendment
Agreement: collaboration
Counterparty: Taiwan Carbon Nano Technology Corporation
Value: NT$5 million (approximately USD$161,000)
Effective: 2024-01-09

Exact text from the filing

On January 9, 2024, the Company and TCNT entered into an addendum to the Product Development Agreement (“Addendum Agreement”) in connection with the scope of co-development and certain terms.

View on SEC.gov

Browse all material agreements →

Ainos, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-000521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.